LT2699261T - Osteoporozės gydymo būdas - Google Patents

Osteoporozės gydymo būdas

Info

Publication number
LT2699261T
LT2699261T LTEP12717002.5T LT12717002T LT2699261T LT 2699261 T LT2699261 T LT 2699261T LT 12717002 T LT12717002 T LT 12717002T LT 2699261 T LT2699261 T LT 2699261T
Authority
LT
Lithuania
Prior art keywords
treating osteoporosis
osteoporosis
treating
Prior art date
Application number
LTEP12717002.5T
Other languages
English (en)
Inventor
Javier SAN MARTIN
Scott Wasserman
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of LT2699261T publication Critical patent/LT2699261T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Removal Of Specific Substances (AREA)
  • Steroid Compounds (AREA)
LTEP12717002.5T 2011-04-19 2012-04-18 Osteoporozės gydymo būdas LT2699261T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477065P 2011-04-19 2011-04-19
PCT/US2012/034107 WO2012145417A1 (en) 2011-04-19 2012-04-18 Method for treating osteoporosis

Publications (1)

Publication Number Publication Date
LT2699261T true LT2699261T (lt) 2018-11-12

Family

ID=46000402

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP18182009.3T LT3404041T (lt) 2011-04-19 2012-04-18 Osteoporozės gydymo būdas
LTEP12717002.5T LT2699261T (lt) 2011-04-19 2012-04-18 Osteoporozės gydymo būdas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP18182009.3T LT3404041T (lt) 2011-04-19 2012-04-18 Osteoporozės gydymo būdas

Country Status (15)

Country Link
US (1) US20140127192A1 (lt)
EP (2) EP3404041B1 (lt)
AU (1) AU2012245495A1 (lt)
CA (1) CA2833289A1 (lt)
CY (2) CY1121527T1 (lt)
DK (2) DK2699261T3 (lt)
ES (2) ES2685479T3 (lt)
HR (2) HRP20181649T1 (lt)
HU (1) HUE052094T2 (lt)
LT (2) LT3404041T (lt)
PL (2) PL3404041T3 (lt)
PT (2) PT3404041T (lt)
RS (2) RS57877B1 (lt)
SI (2) SI2699261T1 (lt)
WO (1) WO2012145417A1 (lt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103251948A (zh) 2008-04-11 2013-08-21 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
CN107973851A (zh) 2010-11-30 2018-05-01 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
EP3285792B1 (en) * 2015-04-20 2020-11-04 The Board of Regents of The University of Texas System Clec11a is a bone growth agent
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
ATE338120T2 (de) 1998-11-27 2006-09-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EA200901031A1 (ru) 2007-02-02 2010-04-30 Новартис Аг Модуляторы склеростин-связывающих партнеров для лечения костных расстройств
KR101123487B1 (ko) 2007-03-20 2012-03-23 일라이 릴리 앤드 캄파니 항?스클레로스틴 항체
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CN101951954A (zh) 2007-11-02 2011-01-19 诺瓦提斯公司 调节低密度脂蛋白受体相关蛋白6(lrp6)的分子和方法
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2010100200A2 (en) 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders

Also Published As

Publication number Publication date
RS60835B1 (sr) 2020-10-30
US20140127192A1 (en) 2014-05-08
PL3404041T3 (pl) 2020-12-14
PT3404041T (pt) 2020-07-30
CA2833289A1 (en) 2012-10-26
DK3404041T3 (da) 2020-08-24
CY1121527T1 (el) 2020-05-29
DK2699261T3 (en) 2018-09-17
ES2685479T3 (es) 2018-10-09
CY1123513T1 (el) 2022-03-24
ES2823240T3 (es) 2021-05-06
EP2699261B1 (en) 2018-07-11
SI2699261T1 (sl) 2018-11-30
SI3404041T1 (sl) 2020-11-30
LT3404041T (lt) 2020-08-25
HRP20181649T1 (hr) 2018-12-14
EP2699261A1 (en) 2014-02-26
HRP20201366T1 (hr) 2020-11-27
EP3404041B1 (en) 2020-07-22
HUE052094T2 (hu) 2021-04-28
PT2699261T (pt) 2018-10-22
EP3404041A1 (en) 2018-11-21
WO2012145417A1 (en) 2012-10-26
PL2699261T3 (pl) 2018-12-31
RS57877B1 (sr) 2018-12-31
AU2012245495A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
HK1201040A1 (en) Method for treating osteoporosis
PL2685961T3 (pl) Sposób leczenia urazu neurologicznego
ZA201400005B (en) Method for treating eczema
EP2698464A4 (en) WASHING METHOD
GB201118838D0 (en) Process for treating an underground formation
ZA201208219B (en) Method for treating wasterwater
EP2531625A4 (en) PROCESS FOR PROCESSING FRACTURE MATERIALS
EP2650276A4 (en) PROCESS FOR PRODUCTION OF -FLUOROALCOOL
PL2771280T3 (pl) Sposób obróbki skał fosfatowych
EP2716970A4 (en) WASTE MELTING PROCESS
HRP20181649T1 (hr) Metoda liječenja osteoporoze
HK1202297A1 (en) Methods for treating acne
PL2691219T3 (pl) Sposób obróbki tekstyliów technicznych
HK1252353A1 (zh) 治療精神***症的方法
EP2723348A4 (en) METHOD FOR THE TREATMENT OF ADIPOSITAS
EP2694077A4 (en) METHOD FOR TREATING ASTHENOPY
GB201101219D0 (en) Method
IL228744A0 (en) A method for treating diseases related to interferon alpha
GB201121008D0 (en) Apparatus & method
IL233240A0 (en) A device for treating cuts
EP2676746A4 (en) straightening PROCEDURE
GB201105523D0 (en) Treatment method
GB201111670D0 (en) Method & apparatus
GB201105062D0 (en) Method
GB201104861D0 (en) Method